Images List Premium Download Classic

Type 1 Diabetes

Type 1 Diabetes-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Multi-cbv vaccine for preventing or treating type i diabetes
Vactech Oy
October 05, 2017 - N°20170281748

The invention is directed to a vaccine comprising: i) coxsackie b virus cbv1 and cbv2, and ii) at least one coxsackie b virus selected from cbv3, cbv4, cbv5 and cbv6. The cbvs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective ...
Probiotic bifidobacterium adolescentis strains
Chr. Hansen A/s
September 07, 2017 - N°20170252382

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated ...
Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
Janssen Biotech, Inc.
August 31, 2017 - N°20170247444

The present invention relates to compositions and methods utilizing anti-tnf antibodies having a heavy chain (hc) comprising seq id no:36 and a light chain (lc) comprising seq id no:37 for use in the treatment or prevention of type i diabetes (t1d).
Type 1 Diabetes Patent Pack
Download + patent application PDFs
Type 1 Diabetes Patent Applications
Download + Type 1 Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Type 1 Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Soluble mediator
The Walter And Eliza Hall Institute Of Medical Research
August 17, 2017 - N°20170232061

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a ...
Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
University Of Southern California
August 17, 2017 - N°20170232053

Stem cell-based therapies can potentially reverse organ dysfunction and diseases but the removal of impaired tissue and reactivation of the program leading to organ regeneration pose major challenges. In mice, a four-day fasting mimicking diet (fmd) induces a step-wise expression of sox17 and pdx-1, resembling that observed during pancreatic development and followed by ngn3-driven generation of insulin-producing β...
Use of dehydroeburicoic acid from antrodia camphorata in the treatment or prevention of diabetes and ...
University Of Southern California
August 03, 2017 - N°20170216384

The present invention provides a method for treating type 1 diabetes, hyperlipidemia or hepatic lipid accumulation by using dehydroeburicoic acid, as well as a method for decreasing levels of blood glucose, plasma total cholesterol, and triglyceride, and increasing insulin levels; and a method for decreasing hepatic balloon degeneration; and increasing expression levels of membrane glut4 and phospho-akt in myotubes; and enhancing ...
Type 1 Diabetes Patent Pack
Download + patent application PDFs
Type 1 Diabetes Patent Applications
Download + Type 1 Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Type 1 Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Small molecule inhibitors of stat3 with anti-tumor activity
University Of Central Florida Research Foundation.
July 20, 2017 - N°20170202795

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e. G., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but ...
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
Boehringer Ingelheim International Gmbh
July 06, 2017 - N°20170189437

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, ...
Novel combination of naturally occurring compounds to assist with suspected mycobacterial infections related to autoimmune ...
Boehringer Ingelheim International Gmbh
June 22, 2017 - N°20170173059

The novel aspect of this invention is that it is a unique formulation of naturally occurring compounds with a unique intention to assist the concerns associated with autoimmune conditions, mainly inflammatory bowel disease (collectively crohn's, ulcerative colitis, irritable bowel syndrome), type 1 diabetes, multiple sclerosis, psoriasis and the suspected infection of the pathogen mycobacterium avium sub-species paratuberculosis (map). Furthermore, its intent ...
Antidiabetic medications
Boehringer Ingelheim International Gmbh
June 22, 2017 - N°20170173027

Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.
Mutation for type i diabetes mellitus and animal model
Medizinische Hochschule Hannover
June 15, 2017 - N°20170164589

The invention relates to a mutation in the dock8 encoding gene that is causative for type 1 diabetes mellitus at least in the rat (rattus norvegicus) or mouse, the rat or mouse preferably having an mhc predisposing towards type 1 diabetes mellitus and/or a mutation in the von willebrand factor vwa2. Embodiments of the invention comprise a process for generating a ...
Means and methods for determining risk of type-1 diabetes by serum protein biomarkers
Turun Yliopisto
June 08, 2017 - N°20170160276

The present invention relates to methods for predicting a risk of a subject for type 1 diabetes (t1d) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.
Crystalline solvate forms of a pharmaceutical
Neurmedix, Inc.
June 01, 2017 - N°20170152281

The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates. The invention further relates to solid ...
Type 1 Diabetes Patent Pack
Download + patent application PDFs
Type 1 Diabetes Patent Applications
Download + Type 1 Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Type 1 Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Velocity-weighting model predictive control of an artificial pancreas for type 1 diabetes applications
Neurmedix, Inc.
May 25, 2017 - N°20170143899

Methods, devices, algorithms, and systems controlling insulin delivery employ velocity-weighting. Predicted glucose outcomes are penalized with a cost modulated by a factor that is a function of the glucose velocity, wherein glucose outcomes are penalized increasingly less for increasingly negative glucose velocities, when glucose level is high, and/or wherein a hyperglycemic glucose value that is already converging to the ...
Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing ...
Hyundai Pharm Co., Ltd.
April 27, 2017 - N°20170114072

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (camp) by activating g protein-coupled receptor 119 (gpr-119) and simultaneously exhibits weight loss and hypoglycemic effects ...
Inhibition of gliadin peptides
Alba Therapeutics Corporation
April 06, 2017 - N°20170096451

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases ...
Compositions and methods for treating type 1 and type 2 diabetes and related disorders
Salk Institute For Biological Studies
March 30, 2017 - N°20170087189

The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.
Nutritional compositions comprising a lipophilic active ingredient
Abbott Laboratories
March 30, 2017 - N°20170086481

Disclosed embodiments provide methods and compositions for improving the metabolic health of consumers. Bovine beta-casein, a major component of milk from cattle, has many genetic variants. Certain genetic variants, a1 in particular, have been associated with type 1 diabetes. The disclosed methods and compositions include reduced amounts of genetic variants of beta-casein that have been associated with diabetes. In some embodiments, ...
Neo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith
Symbiocelltech, Llc
March 16, 2017 - N°20170073641

Described are neo-islets comprising: a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells where the cells have been treated so as to facilitate redifferentiation. Further described herein are methods of generating neo-islets, the methods comprising: culturing a) dedifferentiated islet cells and mesenchymal and/or adipose stem ...
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
Novartis Ag
March 09, 2017 - N°20170065678

The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e. G. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, ...
Substituted pyridazines as prostacyclin receptor modulators
Arena Pharmaceuticals, Inc.
March 02, 2017 - N°20170057931

Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood ...
Loading